To evaluate the role of
ghrelin in cardiac
fibrosis after
myocardial infarction (MI) and to investigate the underlying mechanisms of
ghrelin-regulated Nrf2/
NADPH/ROS pathway-mediated cardioprotection, the profile of Nrf2,
fibrosis markers, and oxidative stress markers were characterized in a rat model of MI and
Angiotensin II (Ang II)-stimulated cardiac fibroblasts (CFs). The effects of
ghrelin on cardiac function,
fibrosis and oxidative stress were investigated after MI in vivo. The role of
ghrelin in CF migration and proliferation was evaluated in Ang II-stimulated CFs in vitro. Inhibition of
ghrelin receptors using the antagonist,
d-Lys3-GHRP-6, in addition to
ghrelin was employed in MI and CFs to investigate the direct effect of
ghrelin on cardiac
fibrosis. Loss function of Nrf2 in CFs was performed to investigate the effect of
ghrelin-regulated Nrf2 on oxidative stress and cardiac
fibrosis.
Ghrelin improved the post-MI cardiac function and reduced cardiac
fibrosis. This phenotype is associated with the upregulation of Nrf2 and downregulation of fibrotic
proteins,
NADPH oxidase and ROS production. In line with in vivo findings,
ghrelin attenuated Ang II-stimulated CF migration, proliferation, and oxidative stress in vitro. Inhibition of the
ghrelin receptor or knockdown of Nrf2 abolished the beneficial effects of
ghrelin on MI or Ang II-stimulated cardiac fibroblasts. In conclusion,
ghrelin ameliorates post-MI and Ang II-induced cardiac
fibrosis by activating Nrf2, which in turn inhibits the
NADPH/ROS pathway.